187 related articles for article (PubMed ID: 23675426)
1. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.
Malm M; Kronqvist N; Lindberg H; Gudmundsdotter L; Bass T; Frejd FY; Höidén-Guthenberg I; Varasteh Z; Orlova A; Tolmachev V; Ståhl S; Löfblom J
PLoS One; 2013; 8(5):e62791. PubMed ID: 23675426
[TBL] [Abstract][Full Text] [Related]
2. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
4. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
[TBL] [Abstract][Full Text] [Related]
5. Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.
Orlova A; Malm M; Rosestedt M; Varasteh Z; Andersson K; Selvaraju RK; Altai M; Honarvar H; Strand J; Ståhl S; Tolmachev V; Löfblom J
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1450-9. PubMed ID: 24622956
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
7. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
Grimm S; Salahshour S; Nygren PÅ
N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
[TBL] [Abstract][Full Text] [Related]
8. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules.
Kronqvist N; Malm M; Göstring L; Gunneriusson E; Nilsson M; Höidén Guthenberg I; Gedda L; Frejd FY; Ståhl S; Löfblom J
Protein Eng Des Sel; 2011 Apr; 24(4):385-96. PubMed ID: 21177282
[TBL] [Abstract][Full Text] [Related]
9. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
10. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
12. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
13. Increasing thermal stability and improving biodistribution of VEGFR2-binding affibody molecules by a combination of in silico and directed evolution approaches.
Güler R; Svedmark SF; Abouzayed A; Orlova A; Löfblom J
Sci Rep; 2020 Oct; 10(1):18148. PubMed ID: 33097752
[TBL] [Abstract][Full Text] [Related]
14. A recombinant affitoxin derived from a HER3 affibody and diphteria-toxin has potent and selective antitumor activity.
Nazari M; Emamzadeh R; Jahanpanah M; Yazdani E; Radmanesh R
Int J Biol Macromol; 2022 Oct; 219():1122-1134. PubMed ID: 36041577
[TBL] [Abstract][Full Text] [Related]
15. Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells.
Nazari M; Zamani Koukhaloo S; Mousavi S; Minai-Tehrani A; Emamzadeh R; Cheraghi R
Macromol Biosci; 2019 Nov; 19(11):e1900159. PubMed ID: 31531954
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
17. Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.
Schardt JS; Oubaid JM; Williams SC; Howard JL; Aloimonos CM; Bookstaver ML; Lamichhane TN; Sokic S; Liyasova MS; O'Neill M; Andresson T; Hussain A; Lipkowitz S; Jay SM
Mol Pharm; 2017 Apr; 14(4):1047-1056. PubMed ID: 28248115
[TBL] [Abstract][Full Text] [Related]
18. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
[TBL] [Abstract][Full Text] [Related]
19. Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Rinne SS; Leitao CD; Mitran B; Bass TZ; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Jan; 9(1):655. PubMed ID: 30679757
[TBL] [Abstract][Full Text] [Related]
20. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
